GlassScriptPhysician profile
Daniela Turacova
NPI 1972685170
$5,862.63
in general payments reported to CMS, 2019-2025
37 companies · $947 in 2025
The $947 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $449 · 2021: $1,311 · 2022: $1,075 · 2023: $1,129 · 2024: $826 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,902.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,588.91 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $976.78 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $974.09 | 2020-2025 | Vraylar, Linzess, Viberzi |
| Pfizer INC. | $312.57 | 2021-2025 | |
| Novo Nordisk INC | $243.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $157.63 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.89 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.51 | 2022 | |
| Idorsia Pharmaceuticals US INC | $106.03 | 2022-2023 | Quviviq |
| Eisai INC. | $97.77 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $95.50 | 2021 | |
| Nestle Healthcare Nutrition INC. | $83.52 | 2020-2023 | |
| Daiichi Sankyo INC. | $82.57 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $76.85 | 2022-2024 | Seglentis, Zoryve |
| Ardelyx, INC. | $75.85 | 2024 | Ibsrela |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Turacova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.